SIPEF financials
SIPEF
Country: BE Reporting currency: USD Latest annual report: 2024-12-31
LEI:
549300NN3PC8KDD43S24 Financial statements
(USD, as reported — unscaled; 124 line items across 2 annual periods)
| Line item | 2024 | 2023 |
|---|---|---|
| Income statement | ||
| Revenue | $443.8M | $443.9M |
| Cost of sales | $286.6M | $294.4M |
| Gross profit | $159.6M | $149.7M |
| Operating profit (EBIT) | $104.1M | $108.0M |
| Net finance income / (cost) | -$6.6M | $839.0K |
| Finance costs | $3.0M | $2.1M |
| Profit before tax | $97.5M | $108.8M |
| Income tax expense | $25.9M | $31.1M |
| Profit for the year | $70.2M | $76.4M |
| — attributable to owners | $65.8M | $72.7M |
| — attributable to NCI | $4.4M | $3.6M |
| Total comprehensive income | $70.3M | $75.6M |
| Cash flow statement | ||
| Cash generated from operations | $164.7M | $178.8M |
| Net cash from operating activities | $133.0M | $122.6M |
| Income taxes paid | $31.6M | $56.2M |
| Net cash from investing activities | -$94.7M | -$116.8M |
| Purchase of PP&E (capex) | $55.2M | $74.4M |
| Purchase of intangibles | $40.0K | $9.0K |
| Net cash from financing activities | -$30.0M | -$38.6M |
| Dividends paid | $24.6M | $36.6M |
| Net change in cash | $8.3M | -$32.8M |
| Balance sheet | ||
| Total assets | $1.12B | $1.08B |
| Non-current assets | $946.0M | $907.8M |
| Intangible assets & goodwill | $104.8M | $104.8M |
| Current assets | $176.4M | $172.4M |
| Inventories | $46.1M | $47.2M |
| Trade & other receivables | $47.4M | $29.9M |
| Cash & equivalents | $19.9M | $11.5M |
| Total equity | $935.8M | $888.8M |
| — attributable to owners | $898.4M | $853.8M |
| Non-controlling interests | $37.4M | $35.0M |
| Non-current liabilities | $78.4M | $78.5M |
| Lease liabilities (non-current) | $1.4M | $2.0M |
| Current liabilities | $108.2M | $113.0M |
| Current portion of long-term borrowings | $0 | $18.0M |
| Lease liabilities (current) | $626.0K | $675.0K |
| Trade & other payables | $59.4M | $55.1M |
| Deferred tax liabilities | $52.7M | $52.5M |
| Derived metrics | ||
| Free cash flow | $77.9M | $48.2M |
| Operating margin | 23.5% | 24.3% |
| Net margin | 15.8% | 17.2% |
| Return on equity | 7.5% | 8.6% |
| Cash conversion ratio | 1.89× | 1.61× |
| Capex coverage | 2.41× | 1.65× |
| Other reported items | ||
| Adjustments For Depreciation and Amortisation Expense | $55.8M | $52.7M |
| Adjustments For Finance Income Cost | -$1.4M | -$270.0K |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | -$2.6M | -$1.6M |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | $6.2M | $186.0K |
| Adjustments For Gains Losses On Change In Fair Value of Derivatives | -$1.3M | -$3.0K |
| Adjustments For Provisions | $2.0M | $2.3M |
| Adjustments For Sharebased Payments | $201.0K | $163.0K |
| Adjustments For Unrealised Foreign Exchange Losses Gains | $2.0M | $0 |
| Basic Earnings Loss Per Share From Continuing Operations | $6.33 | $6.99 |
| Bearer Plants | $320.9M | $326.7M |
| Cash and Cash Equivalents If Different From Statement of Financial Position | $19.9M | $11.6M |
| Cash Flows From Used In Operations Before Changes In Working Capital | $162.9M | $162.8M |
| Comprehensive Income Attributable To Noncontrolling Interests | $4.5M | $3.6M |
| Comprehensive Income Attributable To Owners of Parent | $65.8M | $72.0M |
| Current Advances | $3.9M | $3.4M |
| Current Biological Assets | $13.5M | $11.1M |
| Current Derivative Financial Assets | $0 | $780.0K |
| Current Derivative Financial Liabilities | $1.1M | $0 |
| Current Financial Liabilities | $36.5M | $41.0M |
| Current Investments | $1.0K | $1.0K |
| Current Tax Assets Current | $7.5M | $6.9M |
| Current Tax Liabilities Current | $6.6M | $10.6M |
| Deferred Tax Assets | $16.5M | $15.2M |
| Diluted Earnings Loss Per Share From Continuing Operations | $6.32 | $6.98 |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | $22.4M | $33.8M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | $2.1M | $2.8M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners | $21.2M | — |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | $2.00 | — |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $0 | $0 |
| Equity and Liabilities | $1.12B | $1.08B |
| Finance Income | $1.6M | $1.8M |
| Gains Losses On Exchange Differences On Translation Recognised In Profit Or Loss | -$5.3M | $1.1M |
| Gains Losses On Fair Value Adjustment Biological Assets | $2.4M | $186.0K |
| General and Administrative Expense | $48.5M | $46.2M |
| Income Tax Relating To Cash Flow Hedges of Other Comprehensive Income | -$124.0K | -$214.0K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | $239.0K | -$113.0K |
| Increase Decrease In Working Capital | -$1.8M | -$16.1M |
| Increase Decrease Through Changes In Ownership Interests In Subsidiaries That Do Not Result In Loss of Control | — | -$415.0K |
| Increase Decrease Through Transfers and Other Changes Equity | $1.2M | $70.0K |
| Intangible Assets Other Than Goodwill | $119.0K | $138.0K |
| Interest Paid Classified As Financing Activities | $1.4M | $285.0K |
| Investment Accounted For Using Equity Method | $331.0K | $1.7M |
| Issued Capital | $44.7M | $44.7M |
| Noncurrent Assets Or Disposal Groups Classified As Held For Sale | $7.1M | $13.5M |
| Noncurrent Financial Assets | $112.0K | $112.0K |
| Noncurrent Provisions | $427.0K | $524.0K |
| Noncurrent Receivables | $45.6M | $34.2M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | $23.8M | $23.5M |
| Other Adjustments For Noncash Items | -$69.0K | -$3.0M |
| Other Comprehensive Income | $57.0K | -$773.0K |
| Other Comprehensive Income Attributable To Noncontrolling Interests | $54.0K | -$14.0K |
| Other Comprehensive Income Attributable To Owners of Parent | $3.0K | -$759.0K |
| Other Comprehensive Income Before Tax Cash Flow Hedges | -$495.0K | -$855.0K |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -$418.0K | $268.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | $1.1M | -$512.0K |
| Other Current Assets | $1.9M | $2.0M |
| Other Current Financial Liabilities | $35.9M | $22.3M |
| Other Current Liabilities | $11.2M | $16.9M |
| Other Current Payables | $20.4M | $15.8M |
| Other Current Receivables | $32.9M | $49.5M |
| Other Noncurrent Financial Assets | $112.0K | $112.0K |
| Other Noncurrent Receivables | $45.6M | $34.2M |
| Other Operating Income Expense | -$7.1M | $4.5M |
| Other Property Plant and Equipment | $457.7M | $425.0M |
| Payments To Acquire Or Redeem Entitys Shares | $118.0K | $701.0K |
| Proceeds From Current Borrowings | $13.6M | $17.7M |
| Proceeds From Noncurrent Borrowings | $398.0K | $182.0K |
| Proceeds From Sale Or Issue of Treasury Shares | $1.2M | $608.0K |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | $571.0K | $889.0K |
| Profit Loss From Continuing Operations | $70.2M | $76.4M |
| Profit Loss From Discontinued Operations | $0 | $0 |
| Purchase of Biological Assets | $31.7M | $32.6M |
| Repayments of Current Borrowings | $50.0K | $590.0K |
| Repayments of Noncurrent Borrowings | $18.9M | $18.5M |
| Reserve of Exchange Differences On Translation | -$11.4M | -$11.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | -$1.4M | -$1.3M |
| Share Premium | $108.0M | $108.0M |
| Trade and Other Current Payables To Trade Suppliers | $28.5M | $25.2M |
| Treasury Shares | $10.6M | $11.7M |
| Weighted Average Shares | 10.4M | 10.4M |
Methodology
Every line item above is a fact tagged in SIPEF's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.